{"id":"placebo-plus-s1","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Nausea and vomiting"},{"rate":"20-40%","effect":"Diarrhea"},{"rate":"20-30%","effect":"Anorexia"},{"rate":"10-30%","effect":"Leukopenia"},{"rate":"5-15%","effect":"Thrombocytopenia"},{"rate":"10-20%","effect":"Stomatitis"},{"rate":"5-15%","effect":"Hand-foot syndrome"}]},"_chembl":{"chemblId":"CHEMBL4112960","moleculeType":"Small molecule","molecularWeight":"459.83"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Placebo plus S1","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T07:10:45.588297+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T07:10:51.262965+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Placebo plus S1","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T07:10:51.469324+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4112960/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T07:10:52.717528+00:00"}},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"S1 (tegafur/gimeracil/oteracil potassium) is an oral fluoropyrimidine combination that acts as a prodrug, converting to fluorouracil in tumor cells. The gimeracil component inhibits dihydropyrimidine dehydrogenase to enhance fluorouracil bioavailability, while oteracil protects normal tissues from toxicity. This combination enhances antitumor activity while reducing gastrointestinal side effects compared to 5-FU monotherapy.","oneSentence":"S1 is a combination chemotherapy agent that inhibits thymidylate synthase and dihydropyrimidine dehydrogenase to disrupt DNA synthesis and cell division.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:01:21.136Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T07:10:54.294124+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Gastric cancer"},{"name":"Colorectal cancer"},{"name":"Breast cancer"},{"name":"Pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT07169318","phase":"PHASE1","title":"First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-09-16","conditions":"Influenza","enrollment":78},{"nctId":"NCT06256328","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2024-01-10","conditions":"Gastric Cancer","enrollment":226},{"nctId":"NCT06109779","phase":"PHASE3","title":"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-04","conditions":"Biliary Tract Cancer","enrollment":757},{"nctId":"NCT06576921","phase":"PHASE2","title":"Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2024-11-15","conditions":"Stomach Neoplasms, Immune Checkpoint Inhibitors","enrollment":116},{"nctId":"NCT03615326","phase":"PHASE3","title":"Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-05","conditions":"Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma","enrollment":738},{"nctId":"NCT05651503","phase":"NA","title":"The Effect of Oral Probiotics on Oral Hygiene and Halitosis in Orthodontic Patients.","status":"COMPLETED","sponsor":"University of Athens","startDate":"2022-02-02","conditions":"Halitosis, Probiotics, Orthodontic Appliance Complication","enrollment":120},{"nctId":"NCT06479135","phase":"PHASE3","title":"Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib","status":"RECRUITING","sponsor":"Kartos Therapeutics, Inc.","startDate":"2024-06-03","conditions":"Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis","enrollment":600},{"nctId":"NCT03413384","phase":"PHASE2","title":"To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia","status":"ACTIVE_NOT_RECRUITING","sponsor":"BrainX Corporation","startDate":"2019-02-15","conditions":"Parkinson's Disease Dementia","enrollment":100},{"nctId":"NCT07169240","phase":"PHASE1","title":"Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BT-114143 Injection in Healthy Subjects","status":"COMPLETED","sponsor":"ScinnoHub Pharmaceutical Co., Ltd.","startDate":"2023-02-06","conditions":"Healthy Subjects (HS)","enrollment":84},{"nctId":"NCT06262425","phase":"NA","title":"rTMS Over S1 Enhance Motor Learning in Healthy People","status":"COMPLETED","sponsor":"Neuron, Spain","startDate":"2024-01-20","conditions":"Transcranial Magnetic Stimulation, Motor Learning","enrollment":60},{"nctId":"NCT07138300","phase":"NA","title":"Combined Effect of Low Level Laser Therapy and Neural Mobilization on Lumber Disc Prolapse","status":"COMPLETED","sponsor":"Cairo University","startDate":"2025-02-01","conditions":"Low Level Laser Therapy","enrollment":40},{"nctId":"NCT06949033","phase":"PHASE3","title":"Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Zuoyi Jiao","startDate":"2025-05-15","conditions":"Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy","enrollment":668},{"nctId":"NCT06611397","phase":"NA","title":"Discogen for Low Back Pain","status":"RECRUITING","sponsor":"Columbia University","startDate":"2025-03-15","conditions":"Disc Herniation","enrollment":5},{"nctId":"NCT05204732","phase":"NA","title":"Acoustic and Perceptual Effects of Intonation Training in Gender Diverse People","status":"COMPLETED","sponsor":"University Ghent","startDate":"2022-03-30","conditions":"Gender Dysphoria","enrollment":55},{"nctId":"NCT06870474","phase":"NA","title":"Psychoeducational Intervention Against Support Groups for Caregivers","status":"COMPLETED","sponsor":"University of Salamanca","startDate":"2019-01-10","conditions":"Dementia","enrollment":35},{"nctId":"NCT06405113","phase":"PHASE2","title":"FMT+SOX+Sintilimab As First-line Treatment for Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Changzhou No.2 People's Hospital","startDate":"2024-06-01","conditions":"Gastric Cancer","enrollment":198},{"nctId":"NCT05180734","phase":"PHASE3","title":"PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2022-02-10","conditions":"Gastric or Esophagogastric Junction Adenocarcinoma","enrollment":878},{"nctId":"NCT06577649","phase":"NA","title":"Pain and Perceptual Distortion of Face","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2022-09-09","conditions":"Neuropathic Pain, Orofacial Pain","enrollment":12},{"nctId":"NCT06511765","phase":"PHASE3","title":"Anesthetic Block of the Erector Muscles of the Lumbar Spine to Relieve Acute Lumbar Pain: Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"Elsan","startDate":"2024-09-01","conditions":"Lumbago","enrollment":40},{"nctId":"NCT03006705","phase":"PHASE3","title":"Study of Adjuvant ONO-4538 With Resected Gastric Cancer","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2017-01-31","conditions":"Gastric Cancer","enrollment":800},{"nctId":"NCT05797831","phase":"PHASE2, PHASE3","title":"Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer","status":"RECRUITING","sponsor":"Kartos Therapeutics, Inc.","startDate":"2023-07-17","conditions":"Endometrial Cancer","enrollment":268},{"nctId":"NCT05705466","phase":"PHASE1, PHASE2","title":"Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"Kartos Therapeutics, Inc.","startDate":"2023-06","conditions":"Non Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT06192186","phase":"PHASE4","title":"Adebrelimab Combined With SOX Regimen in Preoperative Neoadjuvant Transformation Therapy for Locally Advanced Gastric Adenocarcinoma","status":"UNKNOWN","sponsor":"Yang Jianjun, PhD","startDate":"2023-12-30","conditions":"Locally Advanced Gastric Adenocarcinoma","enrollment":110},{"nctId":"NCT05872685","phase":"PHASE2","title":"Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)","status":"RECRUITING","sponsor":"Yu jiren","startDate":"2023-12-24","conditions":"Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Proficient Mismatch Repair","enrollment":314},{"nctId":"NCT06199596","phase":"NA","title":"Alpha-s1 Casein Hydrolysate on Sleep","status":"COMPLETED","sponsor":"Kuang Tien General Hospital","startDate":"2019-05-01","conditions":"Chronic Insomnia, Polysomnography","enrollment":38},{"nctId":"NCT05733780","phase":"PHASE2","title":"To Evaluate the Safety, Efficacy,and Pharmacokinetics of Orally Administered Prolectin-M","status":"UNKNOWN","sponsor":"Bioxytran Inc.","startDate":"2023-09","conditions":"COVID-19, SARS CoV 2 Infection","enrollment":40},{"nctId":"NCT05908838","phase":"EARLY_PHASE1","title":"Clinical Study of Modified Banxia Xiexin Decoction Treatment on Gastric Cancer","status":"COMPLETED","sponsor":"ShuGuang Hospital","startDate":"2017-01-01","conditions":"Gastric Cancer (Diagnosis)","enrollment":146},{"nctId":"NCT05822180","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Nano-S1","status":"COMPLETED","sponsor":"General Administration of Military Health, Tunisia","startDate":"2021-01-01","conditions":"COVID-19 Pneumonia","enrollment":116},{"nctId":"NCT05757011","phase":"NA","title":"the Effect of Pre-sacral Nerve Block on Post-operative Pain Following Laparoscopic Hysterectomy","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2020-01-05","conditions":"Gynecology","enrollment":40},{"nctId":"NCT05271708","phase":"PHASE4","title":"Explore the Short- and Mid-term Effects of Fespixon in Scar Cosmesis Following Cervical or Abdominal Surgery","status":"COMPLETED","sponsor":"National Defense Medical Center, Taiwan","startDate":"2022-01-05","conditions":"Scar","enrollment":46},{"nctId":"NCT04764422","phase":"PHASE1, PHASE2","title":"Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2021-03-20","conditions":"Covid-19, SARS Pneumonia, Pneumonia, Viral","enrollment":455},{"nctId":"NCT05434897","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability and Efficacy of AK3280 Cream on Hypertrophic Scar","status":"UNKNOWN","sponsor":"Shanghai Ark Biopharmaceutical Co., Ltd.","startDate":"2022-07","conditions":"Hypertrophic Scar","enrollment":30},{"nctId":"NCT04518891","phase":"NA","title":"Cognitive Functional Therapy Compared With Sham-treatment for Low Back Pain","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2021-05-17","conditions":"Chronic Low-back Pain","enrollment":152},{"nctId":"NCT02539225","phase":"PHASE2","title":"A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-10-05","conditions":"Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":191},{"nctId":"NCT04120545","phase":"NA","title":"Effectiveness of Microcurrents Therapy in Overactive Bladder.","status":"COMPLETED","sponsor":"University of Las Palmas de Gran Canaria","startDate":"2019-11-04","conditions":"Overactive Bladder, Urinary Incontinence","enrollment":56},{"nctId":"NCT05016934","phase":"PHASE1, PHASE2","title":"Evaluation of Safety and Immunogenicity of a Novel Vaccine for Prevention of Covid-19 in Adults Previously Immunized","status":"WITHDRAWN","sponsor":"Hospital do Coracao","startDate":"2021-11-01","conditions":"Covid19","enrollment":""},{"nctId":"NCT04136600","phase":"PHASE2","title":"EGFR Monoclonal Antibody for Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Shanghai Changzheng Hospital","startDate":"2019-07-01","conditions":"Gastric Cancer, Cetuximab, Nimotuzumab","enrollment":100},{"nctId":"NCT02802514","phase":"PHASE4","title":"A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2016-09-20","conditions":"Diabetes Mellitus","enrollment":5},{"nctId":"NCT03345368","phase":"NA","title":"Effect of rTMS in Combination With a Low-carbohydrate Diet in Patients With Obesity","status":"COMPLETED","sponsor":"Hospital General Ajusco Medio","startDate":"2017-09-26","conditions":"Obesity, Anxiety","enrollment":49},{"nctId":"NCT01059825","phase":"PHASE2","title":"Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-02-24","conditions":"Diabetes Mellitus, Type 2","enrollment":375},{"nctId":"NCT02136303","phase":"NA","title":"Regional Kale as Source of Lutein and Zeaxanthin to Improve Vision of AMD-patients","status":"UNKNOWN","sponsor":"University of Jena","startDate":"2015-02","conditions":"Changes in Macular Pigment Optical Density","enrollment":90},{"nctId":"NCT01855958","phase":"NA","title":"Motor Cortex Plasticity and the Effect of Deep Intramuscular Needling Stimulation Therapy (DIMST) in Osteoarthritis Pain","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2012-02","conditions":"Knee Osteoarthritis, Chronic Pain","enrollment":26},{"nctId":"NCT02592642","phase":"NA","title":"the Evaluation of Four Non-operative Treatments for Degenerative Lumbar Spinal Stenosis","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2014-09","conditions":"Degenerative Lumbar Spinal Stenosis","enrollment":104},{"nctId":"NCT02945267","phase":"PHASE4","title":"Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2016-09","conditions":"Unresectable Pancreatic Cancer","enrollment":60},{"nctId":"NCT02427425","phase":"PHASE4","title":"Effectiveness of Transcutaneous Electrical Nerve Stimulation in Patients With Acute Low Back Pain","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2010-06","conditions":"Low Back Pain","enrollment":71},{"nctId":"NCT00411736","phase":"PHASE4","title":"Scandinavian Cystic Fibrosis Azithromycin Study","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2008-05","conditions":"Cystic Fibrosis","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL4112960"},"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tegafur Gimeracil Oteracil Potassium Capsule"],"phase":"marketed","status":"active","brandName":"Placebo plus S1","genericName":"Placebo plus S1","companyName":"Chinese PLA General Hospital","companyId":"chinese-pla-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"S1 is a combination chemotherapy agent that inhibits thymidylate synthase and dihydropyrimidine dehydrogenase to disrupt DNA synthesis and cell division. Used for Gastric cancer, Colorectal cancer, Breast cancer.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T07:10:54.294124+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}